阿立哌唑和奥氮平治疗首发精神分裂症的对比研究
发布时间：2018-09-11 06:28
【摘要】：[目的]对比分析阿立哌唑、奥氮平治疗首发精神分裂症的疗效、安全性、认知功能、经济负担、社会功能和生活质量。 [方法]40例首发精神分裂症患者随机分为阿立哌唑组20例和奥氮平组20例,口服阿立哌唑或奥氮平治疗180天。于治疗前、治疗90天、治疗180天评定阴性症状和阳性症状量表(PANSS)、个人和社会功能量表(PSP)、SF-36健康调查量表(SF-36),同时做药费调查评估成本效果评定和相关的实验室检查。 [结果]1.疗效方面：两组患者在治疗90天时PANSS评分总分均显著下降(P0.05),两组患者在治疗180天时较治疗90天时PANSS评分总分下降无明显差异(P0.05)；两组之间在治疗90天时、治疗180天时PANSS评分无显著性差异(P0.05)。2.认知功能方面：①两组患者在治疗90天时认知功能各项成绩(除情绪管理、符号编码)均较治疗前明显提高(P0.05),两组患者在治疗180天时较治疗90天时认知功能各项成绩的差异均无统计学意义(P0.05)。②两组之间比较：言语学习能力方面在治疗90天时、治疗180天时阿立哌唑组的改善明显高于奥氮平组(P0.05)；空间广度方面阿立哌唑组在治疗90天时顺行得分和总分较治疗前显著增加(P0.05),治疗180天时较治疗90天时空间广度方面的顺行得分和总分均无明显差异(P0.05),两组在治疗前后比较均无统计学差异(P0.05)。3.安全性方面：①阿立哌唑组在治疗前后体重、空腹血糖、胆固醇及甘油三酯差异均无显著性(P0.05),奥氮平组在治疗90天时体重、空腹血糖、胆固醇及甘油三酯均显著升高(P0.05),治疗180天较治疗90天时体重、空腹血糖、胆固醇及甘油三酯均无明显差异(P0.05)。②阿立哌唑组在治疗90天、治疗180天时胆固醇、低密度脂蛋白水平均低于奥氮平组(P0.05)。③EPS方面两组患者不良反应发生率无明显差异(P0.05)。4.经济负担方面：获得单位疗效的奥氮平治疗组需要256.77元,阿立哌唑治疗组需要206.12元,两组之间差异具有统计学意义(P0.05)。5.社会功能及生活质量方面：①两组患者在治疗90天、治疗180天PSP总分均有显著提高(P0.05),两组之间无明显差别(P0.05)。②两组患者在治疗90天、180天时SF-36各方面均有所提高,差异具有统计学意义(P0.05),两组之间无明显差别(P0.05)。 [结论]阿立哌唑组治疗首发精神分裂症患者记忆功能改善方面高于奥氮平组,对代谢方面的影响要小于奥氮平,且更高效低价。
[Abstract]:[objective] to compare the efficacy, safety, cognitive function, economic burden, social function and quality of life of aripiprazole and olanzapine in the treatment of first-episode schizophrenia. [methods] Forty patients with first-episode schizophrenia were randomly divided into aripiprazole group (n = 20) and olanzapine group (n = 20). Before treatment, 90 days after treatment, 180 days after treatment, (PANSS), personal and social function scale (PSP) SF-36 health survey scale (SF-36) was evaluated, and cost effectiveness evaluation and related laboratory tests were performed. [result] 1. Curative effect: the total scores of PANSS scores in the two groups decreased significantly at the 90th day of treatment (P0.05), and there was no significant difference between the two groups in the total scores of PANSS scores on the 180th day of treatment compared with that of the patients of the 90-day treatment group (P0.05), and between the two groups at the 90th day of treatment, There was no significant difference in PANSS score at 180 days after treatment (P0.05). Cognitive function: 1 two groups of patients in 90 days after treatment cognitive function scores (except emotional management, Symbol coding) was significantly higher than that before treatment (P0.05). There was no significant difference in cognitive performance between the two groups at 180 days after treatment and 90 days after treatment (P0.05). 2 comparison between the two groups: speech learning ability at 90 days after treatment, The improvement of aripiprazole group was significantly higher than that of olanzapine group at 180 days (P0.05). Space span of aripiprazole group at 90 days after treatment and the total score significantly increased compared with before treatment (P0.05), 180 days of treatment compared with the treatment of 90 days of space breadth of the anterograde score and total score of no significant difference (P0.05), the two groups in the treatment of space breadth of the anterograde score and total score (P0.05) There was no statistical difference before and after (P0.05). 3. There was no significant difference in body weight, fasting blood glucose, cholesterol and triglyceride between the two groups before and after treatment (P0.05), but in olanzapine group there was no significant difference in body weight, fasting blood glucose at 90 days after treatment. Cholesterol and triglyceride increased significantly (P0.05). There was no significant difference in body weight, fasting blood glucose, cholesterol and triglyceride between 180 days and 90 days after treatment (P0.05). The level of low density lipoprotein was lower than that of olanzapine group (P0.05) .3There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). 4. Economic burden: the unit efficacy of olanzapine treatment group needed 256.77 yuan, aripiprazole treatment group needed 206.12 yuan, the difference between the two groups was statistically significant (P0.05). 5. In the aspect of social function and quality of life, the total score of PSP was significantly increased in two groups after 90 days of treatment (P0.05), and there was no significant difference between the two groups (P0.05). The difference was statistically significant (P0.05), there was no significant difference between the two groups (P0.05). [conclusion] the improvement of memory function in aripiprazole group is higher than that in olanzapine group.
【学位授予单位】：昆明医科大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R749.3
本文编号：2235882
[Abstract]:[objective] to compare the efficacy, safety, cognitive function, economic burden, social function and quality of life of aripiprazole and olanzapine in the treatment of first-episode schizophrenia. [methods] Forty patients with first-episode schizophrenia were randomly divided into aripiprazole group (n = 20) and olanzapine group (n = 20). Before treatment, 90 days after treatment, 180 days after treatment, (PANSS), personal and social function scale (PSP) SF-36 health survey scale (SF-36) was evaluated, and cost effectiveness evaluation and related laboratory tests were performed. [result] 1. Curative effect: the total scores of PANSS scores in the two groups decreased significantly at the 90th day of treatment (P0.05), and there was no significant difference between the two groups in the total scores of PANSS scores on the 180th day of treatment compared with that of the patients of the 90-day treatment group (P0.05), and between the two groups at the 90th day of treatment, There was no significant difference in PANSS score at 180 days after treatment (P0.05). Cognitive function: 1 two groups of patients in 90 days after treatment cognitive function scores (except emotional management, Symbol coding) was significantly higher than that before treatment (P0.05). There was no significant difference in cognitive performance between the two groups at 180 days after treatment and 90 days after treatment (P0.05). 2 comparison between the two groups: speech learning ability at 90 days after treatment, The improvement of aripiprazole group was significantly higher than that of olanzapine group at 180 days (P0.05). Space span of aripiprazole group at 90 days after treatment and the total score significantly increased compared with before treatment (P0.05), 180 days of treatment compared with the treatment of 90 days of space breadth of the anterograde score and total score of no significant difference (P0.05), the two groups in the treatment of space breadth of the anterograde score and total score (P0.05) There was no statistical difference before and after (P0.05). 3. There was no significant difference in body weight, fasting blood glucose, cholesterol and triglyceride between the two groups before and after treatment (P0.05), but in olanzapine group there was no significant difference in body weight, fasting blood glucose at 90 days after treatment. Cholesterol and triglyceride increased significantly (P0.05). There was no significant difference in body weight, fasting blood glucose, cholesterol and triglyceride between 180 days and 90 days after treatment (P0.05). The level of low density lipoprotein was lower than that of olanzapine group (P0.05) .3There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). 4. Economic burden: the unit efficacy of olanzapine treatment group needed 256.77 yuan, aripiprazole treatment group needed 206.12 yuan, the difference between the two groups was statistically significant (P0.05). 5. In the aspect of social function and quality of life, the total score of PSP was significantly increased in two groups after 90 days of treatment (P0.05), and there was no significant difference between the two groups (P0.05). The difference was statistically significant (P0.05), there was no significant difference between the two groups (P0.05). [conclusion] the improvement of memory function in aripiprazole group is higher than that in olanzapine group.
【学位授予单位】：昆明医科大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R749.3
【参考文献】
相关期刊论文 前5条
1 徐富玲;陈云辉;马俊国;;奥氮平、利培酮、阿立哌唑、氯氮平引起患者心电图异常观察及对策[J];齐齐哈尔医学院学报;2011年02期
2 汤庆军;;阿立哌唑与奥氮平对首发精神分裂症患者体质量及糖脂代谢影响的对比研究[J];精神医学杂志;2011年05期
3 杨绪娜;朱峰;李乐华;;非典型抗精神病药对首发精神分裂症患者记忆功能的影响[J];中国临床心理学杂志;2011年01期
4 曹长安;高欢;郭金宏;廖春平;朴胜斌;王鹏;梁健雄;张文顺;;新型抗精神病药物对女性精神分裂症泌乳素、甲状腺激素的影响[J];中国民康医学;2008年17期
5 司天梅,杨建中,舒良,王希林,孔庆梅,周沫,李雪霓,刘粹;阳性和阴性症状量表(PANSS,中文版)的信、效度研究[J];中国心理卫生杂志;2004年01期
，本文编号：2235882
本文链接：https://www.wllwen.com/yixuelunwen/jsb/2235882.html
最近更新
教材专著
